4ZRO image
Entry Detail
PDB ID:
4ZRO
Title:
2.1 A X-Ray Structure of FIPV-3CLpro bound to covalent inhibitor
Biological Source:
PDB Version:
Deposition Date:
2015-05-12
Release Date:
2015-10-14
Method Details:
Experimental Method:
Resolution:
2.06 Å
R-Value Free:
0.23
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:3C-like proteinase
Chain IDs:A, B, C, D
Chain Length:299
Number of Molecules:4
Biological Source:Feline coronavirus (strain FIPV WSU-79/1146)
Polymer Type:polypeptide(L)
Description:Bounded inhibitor of N-(tert-butoxycarbonyl)-L-seryl-L-valyl-N-{(2S)-5-ethoxy-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pentan-2-yl}-L-leucinamide
Chain IDs:E, F, G, H
Chain Length:5
Number of Molecules:4
Biological Source:synthetic construct
Ligand Molecules
Peptide-like Molecules
PRD_002174
Primary Citation
X-ray structure and inhibition of the feline infectious peritonitis virus 3C-like protease: Structural implications for drug design.
Bioorg.Med.Chem.Lett. 25 5072 5077 (2015)
PMID: 26592814 DOI: 10.1016/j.bmcl.2015.10.023

Abstact

Feline infectious peritonitis (FIP) is a deadly disease that effects both domestic and wild cats and is caused by a mutation in feline coronavirus (FCoV) that allows the virus to replicate in macrophages. Currently, there are no treatments or vaccines available for the treatment of FIP even though it kills approximately 5% of cats in multi-cat households per year. In an effort to develop small molecule drugs targeting FIP for the treatment of cats, we screened a small set of designed peptidomimetic inhibitors for inhibition of FIPV-3CL(pro), identifying two compounds with low to sub-micromolar inhibition, compound 6 (IC50=0.59±0.06 μM) and compound 7 (IC50=1.3±0.1 μM). We determined the first X-ray crystal structure of FIPV-3CL(pro) in complex with the best inhibitor identified, compound 6, to a resolution of 2.10 Å to better understand the structural basis for inhibitor specificity. Our study provides important insights into the structural requirements for the inhibition of FIPV-3CL(pro) by peptidomimetic inhibitors and expands the current structural knowledge of coronaviral 3CL(pro) architecture.

Legend

Protein

Chemical

Disease

Primary Citation of related structures